SCHEMBL8215224

SCHEMBL8215224

COC(=O)c1ccc(O)c(NC/C=C(\C)CCC=C(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 4/20 0.45
▸ ACHE P22303 1/20 0.45
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ XDH P47989 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ PTGES O14684 2/20 0.42
▸ APP P05067 1/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8222242 0.99 ACHE (0.47) TRPV1ACHECA12CA1CA2
SCHEMBL8223338 0.87 PTGES (0.47) TRPV1PTGESAPPHDAC3HDAC4
SCHEMBL8219287 0.87 BACE1 (0.53) TRPV1ACHEAPP
SCHEMBL8223345 0.86 PTGES (0.47) TRPV1PTGESAPPHDAC3HDAC4
SCHEMBL3590181 0.86 PTGES (0.47) TRPV1PTGESAPPHDAC3HDAC4
SCHEMBL3609256 0.86 PTGES (0.47) TRPV1PTGESAPPHDAC3HDAC4
SCHEMBL8214969 0.82 PTGES (0.42) TRPV1PTGESAPPHDAC3HDAC4
SCHEMBL8223744 0.82 CREBBP (0.42) TRPV1PTGESAPPHDAC3HDAC4
SCHEMBL3597724 0.80 TRPV1 (0.39) TRPV1PTGESAPPHDAC3HDAC4
SCHEMBL3597726 0.80 TRPV1 (0.39) TRPV1PTGESAPPHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2010-02-18 — — US disclosed
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2010-02-18 — — US disclosed
WO-2008015240-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2008-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS PNMT, PSEN1, SNCA TRPV1 1245/4885ACHE 23/4885CA12 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback